Blood-Based DNA Methylation Biomarkers to Identify Risk and Progression of Cardiovascular Disease
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26052355 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Tarryn Willmer und 4 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Research and Innovation Platform, South African Medical Research Council, Tygerberg 7505, South Africa. Hauptthemen laut MEDLINE: DNA Methylation, Cardiovascular Diseases, Biomarkers. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 154 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation, South African Medical Research Council (SAMRC), National Research Foundation CSUR.
Abstract (Originalsprache)
Non-communicable diseases (NCDs) are the leading cause of death worldwide, with cardiovascular disease (CVD) accounting for half of all NCD-related deaths. The biological onset of CVD may occur long before the development of clinical symptoms, hence the urgent need to understand the molecular alterations underpinning CVD, which would facilitate intervention strategies to prevent or delay the onset of the disease. There is evidence to suggest that CVD develops through a complex interplay between genetic, lifestyle, and environmental factors. Epigenetic modifications, including DNA methylation, serve as proxies linking genetics and the environment to phenotypes and diseases. In the past decade, a growing list of studies has implicated DNA methylation in the early events of CVD pathogenesis. In this regard, screening for these epigenetic marks in asymptomatic individuals may assist in the early detection of CVD and serve to predict the response to therapeutic interventions. This review discusses the current literature on the relationship between blood-based DNA methylation alterations and CVD in humans. We highlight a set of differentially methylated genes that show promise as candidates for diagnostic and prognostic CVD biomarkers, which should be prioritized and replicated in future studies across additional populations. Finally, we discuss key limitations in DNA methylation studies, including genetic diversity, interpatient variability, cellular heterogeneity, study confounders, different methodological approaches used to isolate and measure DNA methylation, sample sizes, and cross-sectional study design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biomedical Research and Innovation Platform, South African Medical Research Council, Tygerberg 7505, South Africa.
- Centre for Cardio-metabolic Research in Africa, Division of Medical Physiology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg 7505, South Africa.
- Division of Cell Biology, Department of Human Biology, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.
- Department of Biochemistry and Microbiology, University of Zululand, Kwa-Dlangezwa 3886, South Africa.
ORCID-Profile: Tarryn Willmer, Lawrence Mabasa, Jyoti Sharma, Christo J F Muller, Rabia Johnson
Förderung
- National Research Foundation
- South African Medical Research Council (SAMRC)
- National Research Foundation CSUR
Zitieren
APA
Willmer, T., Mabasa, L., Sharma, J., Muller, C. J. F., & Johnson, R. (2025). Blood-Based DNA Methylation Biomarkers to Identify Risk and Progression of Cardiovascular Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26052355
Vancouver
Willmer T, Mabasa L, Sharma J, Muller CJF, Johnson R. Blood-Based DNA Methylation Biomarkers to Identify Risk and Progression of Cardiovascular Disease. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26052355
BibTeX
@article{Willmer2025,
author = {Willmer, Tarryn and Mabasa, Lawrence and Sharma, Jyoti and Muller, Christo J F and Johnson, Rabia},
title = {Blood-Based DNA Methylation Biomarkers to Identify Risk and Progression of Cardiovascular Disease},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26052355}
}
EUVIMED